ReviewCurrent cardiology reports2014
Role of HDL in those with diabetes.
Review in Current cardiology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- Mediation effect analysis of lipoprotein levels on BMI and cardiovascular outcomes in patients with heart failure.BMC cardiovascular disorders · 2024Observational
- Correlation of Anthropometry With Plasma Atherogenicity Indices in Subjects With Type 2 Diabetes Mellitus.Cureus · 2024Article
- The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.Journal of diabetes research · 2024Article
- A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.Health science reports · 2023Article
- A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation.Cureus · 2023 · on this mapArticle
- A comparative evaluation of cardiac and neurological safety status of two commonly used oral hypoglycaemic agents in T2-DM Swiss albino mice model.Metabolism open · 2022Article
- The Relationship of 25(OH)DMedicina (Kaunas, Lithuania) · 2022Article
- Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: A cross-sectional study.Frontiers in neurology · 2022Article
- Blood Lead and High-Density Lipoprotein Concentrations in Relation to Human Blood Pressure: A Cross Sectional Study.Frontiers in nutrition · 2022Article
- Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study.Journal of translational medicine · 2020Article
- Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes.Clinical medicine insights. Endocrinology and diabetes · 2019Article
- Serum Lipid Profile and Its Association with Diabetes and Prediabetes in a Rural Bangladeshi Population.International journal of environmental research and public health · 2018Article
- The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.International journal of molecular sciences · 2018Review
- Interactions of Six SNPs in ABCA1gene and Obesity in Low HDL-C Disease in Kazakh of China.International journal of environmental research and public health · 2016Article
- Association between Eight Functional Polymorphisms and Haplotypes in the Cholesterol Ester Transfer Protein (CETP) Gene and Dyslipidemia in National Minority Adults in the Far West Region of China.International journal of environmental research and public health · 2015Article
- Article
- Emerging risk biomarkers in cardiovascular diseases and disorders.Journal of lipids · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with an increased risk of coronary heart disease in prospective population studies and clinical trials of high-risk patients treated with a low to moderate intensity statin. As a result, therapeutic targets were developed to increase concentrations of HDL-C. Subsequently, clinical trials of high-intensity statins have not supported this previously well-established association. In trials of high-intensity statin therapy, low HDL particle concentration (HDL-P) has been associated with an increased risk of future cardiovascular events. Therefore, strategies that increase HDL-C without expanding the pool of HDL-P with its rich proteome/lipidome do not seem to be an effective strategy. In this review, we discuss potential mechanisms of action for the anti-atherogenic effect of HDL and the impact of current and emerging therapies on the functional capacity of HDL-P. Finally, we discuss emerging therapies that increase the concentration and functional properties of HDL.
Indexed as
Identifiers
25199216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.